Lecture Notes

**Lecture Coverage:**
- Competitive Antagonism: Reversible & Irreversible Antagonists
- Non-Competitive Antagonism: Allosteric & Functional Antagonists

---
#### **Competitive Antagonism: Reversible & Irreversible Antagonists**
**Competitive Antagonism**
- Inhibitors compete against Agonists for same receptor
- Potency measured in pA2:$$\Large pA2 = -log(Kd)$$
	- Specificity: Measured by comparing Antagonist pA2 on different receptors

**Examples of Competitive Antagonists**
- Naloxone: Opioid Antagonists at Opioid Receptors

**Differences between Reversible & Irreversible Competitive Antagonists**

|                                   Property                                   |                              Reversible Antagonist                               | Irreversible Antagonists |
| :--------------------------------------------------------------------------: | :------------------------------------------------------------------------------: | :----------------------: |
|                           Antagonist-Receptor Bond                           |                                    Transient                                     |        Permanent         |
|                                  CRC Change                                  |                                 Rightward Shift                                  |      Downward Shift      |
|            <abbr Title="Maximum Response">E<sub>max</sub></abbr>             | <abbr Title="Can still be achieved with higher ligand concentration">Same</abbr> |         Lowered          |
| <abbr Title="Ligand Concentration required to reach 50% of Emax">EC50</abbr> |                                      Higher                                      |            <             |


#### **Non-Competitive Antagonism: Allosteric & Functional Antagonists**
**Allosteric Antagonism**
- Induces Conformation change through binding to allosteric site → ↓ Agonist Affinity / Signal Transduction Ability

**Functional Antagonism**
- Ligands that produces Opposite Effect through:
	- Different receptor from that of Agonist
	- Inhibition of Intermediate Signaling Pathway

**Examples of Non-Competitive Antagonists**
- Different Receptor

|  Ligand  |     Acetylcholine      | Epinephrine |
| :------: | :--------------------: | :---------: |
| Receptor | M2 Muscarinic Receptor |    β AAd    |
|  Effect  |                        |             |

- Inhibition of Intermediate Signaling Pathway


**Differences between Allosteric & Functional Antagonists**

|                                   Property                                   |                              Allosteric Antagonist                               | Functional Antagonists |
| :--------------------------------------------------------------------------: | :------------------------------------------------------------------------------: | :--------------------: |
|                           Antagonist Binding Site                            |                         Allosteric Site of Same Receptor                         |   Different Receptor   |
|                                  CRC Change                                  |                                 Rightward Shift                                  |     Downward Shift     |
|            <abbr Title="Maximum Response">E<sub>max</sub></abbr>             | <abbr Title="Can still be achieved with higher ligand concentration">Same</abbr> |        Lowered         |
| <abbr Title="Ligand Concentration required to reach 50% of Emax">EC50</abbr> |                                      Higher                                      |           <            |